好护士Herbapex品牌怎么样 申请店铺

我要投票 好护士Herbapex在鹿胎膏行业中的票数:188 更新时间:2025-04-20
好护士Herbapex是哪个国家的品牌?「好护士Herbapex」是辽宁上药好护士药业(集团)有限公司旗下著名品牌。该品牌发源于辽宁,由创始人左敏在2004-03-19期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力好护士Herbapex品牌出海!通过在本页面挂载好护士Herbapex品牌的产品链接和联系邮箱,可以提高好护士Herbapex产品曝光!跨境电商爆单神器,目前只要100元/年哦~

好护士Herbapex怎么样

辽宁好护士药业(集团)有限责任公司坐落于世界文化遗产——五女山山城脚下、辽宁省最大的湖泊——桓龙湖畔,1999年12月公司成立,2004年3月与上海实业集团合资,成为中外合资企业,先后通过GMP、ISO9001、ISO14000等多项认证。

目前集团公司可生产3个剂型,42个品种,其中国家中药保护品种15个,国家基本药物26个,独家生产品种7个,国家医保目录品种19个,基本上形成了以乳癖消为代表的乳系列产品,以尫痹片为代表的痹症系列产品,以强肾片为代表的肾系列产品,以益心宁神片为代表的心脑血管系列产品的产品结构群。主导品种乳癖消片作为问世二十多年的老品种,数十年畅销不衰,并成为治疗妇女乳腺病的首选药物,单品种年销售额超亿元,出口到俄罗斯、哈萨克斯坦、乌克兰、东南亚等地区和国家,在俄罗斯获得“梅奇尼克夫”金奖和“巩固民族健康贡献奖”,为中药在国际市场赢得了荣誉;痹症系列药是治疗风湿病、类风湿病的纯中药制剂,由中华中医药学会风湿病分会焦树德教授经十多年临床研究而开发的独家生产品种,采用辩证施治的原则,对症下药,因其纯中药制剂的特点,对患者无毒副反应,因而广受欢迎。

公司拥有现代化的生产厂房和设备,并采用国内最先进的生产技术,生产管理团队拥有执业药师、工程师等多名专业人才,同时又具有丰富的现场管理经验,生产队伍技术熟练,经验丰富。提取车间年处理药材量5000吨,是国家中药现代化示范工程,总投资3500万,建筑面积4500平方米,该车间采用大孔树脂吸附的先进提取技术,装配全自动化控制系统,实现生产全过程的自动化控制。固体制剂车间总投资2900万,建筑面积4100平方米,年产片剂40亿片,胶囊剂5亿粒,引进高速压片机、高效包衣机、全自动包装线等一系列先进设备,提高生产自动化水平。公司的提取技术和制剂水平在国内同行业处于一流水平。

公司技术研发中心为省级技术研发中心、辽宁省工程技术研究中心、本溪市重点实验室、中国医科大学生物制药研究所研发基地、辽宁中医学院实训基地,配备有国内一流的检测、检验、中试设备和专业的技术研发队伍。该中心在注重新产品开发步入生产、储备、研制的同时,一项重要的任务就是对在产品的生产工艺、设备进行研究,以提高生产技术水平。

公司营销网络覆盖全国(除台湾、西藏),现有营销人员近400人,设有特区办事处3个,大区办事处16个。通过专业推广、学术会议等多种形式提高公司和产品的形象和知名度,公司销售额连年创新高。

09年,公司“苍松”商标被评为全国驰名保护,“好护士”商标被评为辽宁省著名商标,这既是对公司以往业绩和知名度的认可,也是公司再上新台阶的一个新起点。“全国企业文化创新单位”、“辽宁省腾龙企业”、“辽宁省用户满意企业”、“辽宁省高新技术企业”、“中国质量万里行辽宁省示范单位”、“辽宁省农业产业化重点龙头企业”、“辽宁省创驰名保护先锋企业”等荣誉称号和资格认证见证了好护士药业曾经的辉煌业绩。以“做好人,做好药”为价值观的好护士药业,在发展中践行着“托起生命的太阳,呵护人类的健康”的企业宗旨,立志成为维护人类生命健康的“好护士”。

Liaoning good nurse Pharmaceutical (Group) Co., Ltd. is located at the foot of wunushan mountain city, the world cultural heritage, and Huanlong lake, the largest lake in Liaoning Province. The company was founded in December 1999. In March 2004, it became a Sino foreign joint venture with Shanghai industrial group. It has passed GMP, ISO9001, ISO14000 and other certifications. At present, the group company can produce 3 dosage forms, 42 varieties, including 15 national traditional Chinese medicine protection varieties, 26 national essential drugs, 7 exclusive production varieties, 19 national medical insurance catalogue varieties, basically forming a series of dairy products represented by Rupixiao, a series of Bi syndrome products represented by Jabi tablet, a series of kidney products represented by Qiangshen tablet, and a series of yixinningshen tablet The product structure group of cardiovascular and cerebrovascular products. The leading product Rupixiao tablet, as an old one that has been published for more than 20 years, has been selling well for decades, and has become the first choice drug for the treatment of women's breast disease. The annual sales of a single product has exceeded 100 million yuan, and it has been exported to Russia, Kazakhstan, Ukraine, Southeast Asia and other regions and countries. In Russia, it has won the gold medal of "Mechnikov" and the award of "contribution to the consolidation of national health", and it is a Chinese medicine in China The international market has won the honor; arthralgia series medicine is a pure Chinese medicine preparation for treating rheumatism and rheumatoid diseases. Professor Jiao Shude, the rheumatic branch of the Chinese society of traditional Chinese medicine, has developed an exclusive production variety after more than ten years of clinical research. It is based on the principle of dialectical treatment. It is widely welcomed because of the characteristics of its pure Chinese medicine preparation and its non-toxic side effects on patients. The company has modern production plant and equipment, and adopts the most advanced production technology in China. The production management team has many professional talents such as licensed pharmacists and engineers, as well as rich on-site management experience. The production team is skilled and experienced. The annual processing capacity of the extraction workshop is 5000 tons, which is a national modernization demonstration project of traditional Chinese medicine, with a total investment of 35 million yuan and a building area of 4500 square meters. The workshop adopts the advanced extraction technology of macroporous resin adsorption, assembles the full automatic control system, and realizes the automatic control of the whole production process. The total investment of the solid preparation workshop is 29 million, with a construction area of 4100 square meters. The annual output of the workshop is 4 billion tablets and 500 million capsules. A series of advanced equipment such as high-speed tablet pressing machine, high-efficiency coating machine and automatic packaging line are introduced to improve the production automation level. The company's extraction technology and preparation level are in the first-class level in the same industry in China. The company's technology R & D center is a provincial technology R & D center, Liaoning Engineering Technology Research Center, Benxi Key Laboratory, research and development base of Institute of Biopharmaceutics, China Medical University, and practical training base of Liaoning College of traditional Chinese medicine, equipped with domestic first-class testing, testing, pilot equipment and professional technology R & D team. While the center is focusing on the development of new products into production, storage and development, an important task is to study the production process and equipment of products in process, so as to improve the production technology level. The company's marketing network covers the whole country (except Taiwan and Tibet), with nearly 400 marketing personnel, 3 special zone offices and 16 regional offices. Through professional promotion, academic conferences and other forms to improve the image and popularity of the company and its products, the company's sales volume has reached a new high year after year. In 2009, the company's "Cangsong" trademark was awarded the national well-known protection, "good nurse" trademark was awarded the famous trademark of Liaoning Province, which is not only the recognition of the company's past performance and popularity, but also a new starting point for the company to go to a new level. "National enterprise culture innovation unit", "Liaoning Tenglong enterprise", "Liaoning user satisfaction Enterprise", "Liaoning high tech enterprise", "Liaoning demonstration unit of China's quality wanlihang", "key leading enterprise of agricultural industrialization in Liaoning Province", "Liaoning well-known protection pioneer enterprise" and other honorary titles and qualification certification have witnessed the past Brilliant achievements. The good nurse pharmaceutical industry, with the value of "be a good person, do a good job in medicine", practices the enterprise tenet of "holding up the sun of life, caring for human health" in the development, and is determined to become a "good nurse" to maintain human life and health.

本文链接: https://brand.waitui.com/bd64c2ad9.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

第一资本获批收购Discover

美国联邦储备委员会和货币监理署近日宣布,已批准第一资本金融公司(Capital One)收购发现金融服务公司(Discover Financial Services)的申请。这一交易还将使第一资本间接收购Discover Bank。此前,第一资本于2024年2月20日首次宣布与Discover达成一项最终协议。根据该协议,第一资本将通过全股票交易收购Discover,交易价值为353亿美元。(界面新闻)

2小时前

中信证券:自主科技、受益欧洲资本开支扩张的板块等配置上将占优

中信证券研报表示,贸易战僵持阶段,超预期的刺激和基于妥协的贸易协议都很难发生;僵持阶段比的是两国的经济韧性,中国的政策选项更多、空间更大、能耗更久,对美国而言,7月前大规模的国债到期可能会是特朗普关税政策的第一个动摇点;A股也是中国贸易战中提振信心的关键环节,应充分相信国家维护资本市场稳定的决心,港股可能是阶段性的薄弱环节,但也要看到内地资金依旧整体明显低配港股。配置上,从规避不确定性的角度,自主科技、受益欧洲资本开支扩张的板块、纯内需必选消费、稳定红利以及不依赖短期业绩的题材料将占优。(证券时报)

2小时前

盛和资源:MP公司暂停向中国出口稀土精矿不会对公司生产经营产生重大影响

4月20日,盛和资源(600392)发布公告称,网上出现“美国稀土生产商MP Materials(简称“MP公司”)宣布因关税停止向中国出口稀土精矿”的相关报道,公司就相关情况说明如下:2024年1月,MP公司与公司控股子公司盛和资源(新加坡)国际贸易有限公司再次续签了新的包销协议,盛和资源(新加坡)国际贸易有限公司为MP公司在中国的独家经销商;协议期限2年,到期后可延长1年;包销产品除稀土精矿外,还有其他稀土产品。截至目前,双方签署的包销协议尚在有效期内。目前因加征关税,MP公司暂时停止向中国出口稀土精矿。公司已构建了多元化的稀土原料供应渠道,四川矿、独居石以及其他国家进口矿可以作为替代供应。MP公司暂停向中国出口稀土精矿不会对公司生产经营产生重大影响。(新浪财经)

2小时前

华为将发布兆瓦级超充产品

华为将于4月22日召开2025华为智能电动&智能充电网络战略与新品发布会。据了解,发布会上,华为将发布兆瓦级超充产品。根据华为此前的预告,该兆瓦级充电产品最大充电电流2400安培,最大功率1.5兆瓦,每分钟能补给20度电,15分钟可充满一辆电动重卡(约300度电池容量)。(财联社)

2小时前

马来西亚航空考虑购买中国商飞飞机

据俄罗斯卫星社网站4月20日报道,马来西亚航空正在考虑购买中国国产飞机,中国商飞的三款商用机型C909、C919和C929都在评估范围内。马来西亚航空集团相关负责人18日对媒体表示,公司在制定未来几年的机队扩张计划,正密切评估购买中国商飞公司的飞机,双方团队已有过多轮沟通。报道称,被问及具体对C909、C919和C929中的哪款机型更感兴趣,该负责人表示,所有都在考虑之中,“我们在梳邦国际机场的运营就很适合商飞的小机型”。(界面新闻)

2小时前

本页详细列出关于龙潭山的品牌信息,含品牌所属公司介绍,龙潭山所处行业的品牌地位及优势。
咨询